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Abstract
Renal fibrosis and anaemia are two of the most relevant events in chronic kidney disease. Fibrosis is characterized by the accumulation of extra-
cellular matrix proteins in the glomeruli and tubular interstitium. Anaemia is the consequence of a decrease in erythropoietin production in fibro-
tic kidneys. This work analyses the possibility that the accumulation of abnormal collagens in kidney interstitium could be one of the
mechanisms responsible for erythropoietin decreased synthesis. In renal interstitial fibroblast grown on collagen I, erythropoietin mRNA
expression and HIF-2a protein decreased, whereas focal adhesion kinase protein (FAK) phosphorylation and proteasome activity increased,
compared to cells grown on collagen IV. Proteasome inhibition or FAK inactivation in cells plated on collagen I restored erythropoietin and HIF-
2a expression. FAK inhibition also decreased the collagen I-dependent proteasome activation. In a model of tubulointerstitial fibrosis induced
by unilateral ureteral obstruction in mice, increased collagen I protein content and an almost complete disappearance of erythropoietin mRNA
expression were observed in the ureteral ligated kidney with respect to the contralateral control. Interestingly, erythropoietin synthesis was
recovered in obstructed mice treated with proteasome inhibitor. These data suggest that reduced kidney erythropoietin synthesis could be
caused by the accumulation of abnormal extracellular matrix proteins.
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Introduction
Extracellular matrix (ECM) is one of the main components of the
different tissues and organs. It plays a critical role in maintaining the
structure of tissues, but it also modulates the phenotype of adjacent
cells. ECM is composed by proteins such as laminin, fibronectin and
collagens. In pathophysiological conditions, ECM proteins accumulate
in the tissue, and abnormal ECM components appear in organs in
which they are not usually present [1]. ECM interacts with cells through
different surface transmembrane receptors, including integrins. Inte-
grins are a family of heterodimeric receptors composed by two non-
covalently associated subunits, a and b, which mediate signalling from
ECM to the cellular cytoplasm and generate intracellular signals regulat-
ing multiple actions such as proliferation and survival [2]. The major
signalling pathways are launched by the activation of the well-known
integrin mediators, integrin-linked kinase (ILK) [3] or focal adhesion
kinase (FAK), which causes phosphorylation of other intracellular pro-
teins [4, 5], activating routes as MAPK [6], PI3/AKT [7] or RhoB [8].
In chronic kidney disease (CKD), there is an unusual accumulation
of ECM proteins in the renal interstitium, a finding known as
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interstitial fibrosis. In this process, one of the major fibrillar colla-
gens, collagen type I (COLI), accumulates in the interstitium, whereas
the relative amount of collagen type IV (COLIV) decreases [9]. These
changes in ECM provoke important modifications in the renal struc-
ture, as well as in the function of tubule-interstitial cells, with the pro-
gressive loss of renal function [10–13]. The main mechanism
responsible for excessive pathological extracellular matrix deposition
seems to be the proliferation and activation of interstitial fibroblast to
myofibroblasts and the subsequent increase in ECM synthesis and
release [14–16].
One of the most relevant clinical events in CKD is the anaemia
produced by a decreased erythropoietin (EPO) production [17]. In
adults, EPO is mainly synthesized in the kidney and it is necessary for
effective haematopoiesis. Its production is dependent on oxygen con-
centration [18]. In the last years, several studies have tried to identify
EPO-producing cells in kidney. A number of evidence support that
EPO is synthesized in interstitial fibroblast-like cells in the deep renal
cortex and in the outer renal medulla [19–23]. EPO synthesis is regu-
lated by the transcription factor, hypoxia-inducible factor, HIF [24].
HIF is a heterodimeric basic helix–loop–helix formed by a subunit
regulated by oxygen levels (isoforms HIF1a and HIF2a) and a consti-
tutively expressed b subunit. In the kidney, they are expressed in
tubular epithelial, endothelial, glomerular and interstitial cells [25–
27]. A number of important evidence supports that HIF2a is the main
responsible for the synthesis and regulation of EPO [28–33]. In nor-
moxia conditions, HIFa is hydroxylated by specific iron-dependent
dioxygenase enzymes called prolyl hydroxylases (PHD) [34]. These
enzymes hydroxylate HIFa at specific proline residues, which are rec-
ognized by a tumour suppressor protein, the von Hippel–Lindau pro-
tein (pVHL), and ubiquitined. These post-translational modifications
target HIFa for degradation by proteasome [35–39]. Under hypoxia,
HIFa is not hydroxylated but accumulates and it is bound to HIFb.
This complex acts as a transcription factor inducing transcription of
genes involved in different processes such as angiogenesis, apopto-
sis or metabolism [40].
CKD-related anaemia is usually considered the result of the pro-
gressive loss of EPO-producing interstitial cells. However, taking into
consideration the relevance of ECM proteins in the modulation of cell
phenotype, it may also be suggested that the interstitial fibrosis that
takes place in CKD could also be responsible for the changes in EPO
synthesis. Few studies have been devoted to establishing a link
between ECM proteins and EPO synthesis. A recent study has shown
that, in renal fibrosis, EPO-producing cells possess plasticity and their
transition to myofibroblasts can be the link between anaemia and
renal fibrosis in CKD [41]. However, the mechanism responsible for
these relationships is still unclear. To understand the mechanisms
that may link erythropoietin decreased synthesis and renal fibrosis,
we used an in vitro approach using human renal interstitial fibroblast
cultured on different collagen matrix, and an in vivo model of tubu-
lointerstitial fibrosis induced by unilateral ureteral ligation (UUO) in
mice. Our results suggest that the accumulation of abnormal colla-
gens may be one of the mechanisms involved in the decreased EPO
synthesis. In addition, they show that EPO changes are due to




Foetal calf serum (FCS), foetal bovine serum (FBS), lipofectamine, antibiotics,
Optimen, RNAlater solution, High-Capacity cDNA Reverse Transcription Kit
gene expression assays and anti-GAPDH mouse antibody were from Life
Technologies (Carlsbad, CA, USA). Cell culture medium DMEM was from
Lonza (Basel, Switzerland). Collagen I antibody was from Chemicon Interna-
tional Inc (Ternecula, CA, USA). Antibodies against phosphorylated form of
FAK and GSK and against ILK and total-Fak were from Cell Signalling Technol-
ogy (Danvers, MA, USA). Anti-HIF-2a and anti-erythropoietin antibodies were
from Abcam (Cambridge, UK). Anti-OH-HIF antibody was from Novus Biologi-
cals (Littleton, CO, USA). Anti-rabbit antibody was from Dako (Barcelona,
Spain). Anti-rabbit Cy3 was from Jackson Immunoresearch (West Grove, PA,
USA), and antimouse 488 Alexa and Hoechst were from Molecular Probes
(Barcelona, Spain). Dual-Luciferase Reporter Assay System was from Pro-
mega (Madison, WI, USA). FAK inhibitor 4-amino-5-(4-chloro-phenyl)-7-(t-
butyl)pyrazolo3,4-dpyrimidine (PP2), Fluorogenic substrate Succ-LLVY-AMC
for proteasome activity and proteasome inhibitor MG132 were purchased
from Calbiochem (San Diego, CA, USA). Proteasome inhibitor bortezomib
(Velcade) was from Janssen-Cilag International (Beerse, Belgium). siRNA
negative control and siFAK were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Prolong antifade was from Invitrogen (Barcelona, Spain). Chemilu-
minescence reagent was from Thermo Scientific (Basingstoke, UK). FastStart
DNA master SYBR Green I Kit was from Roche (Mannheim, Germany). Other
reagents and antibodies were from Sigma Chemical (St. Louis, MO, USA).
Primers
The following primers were used: EPO human, 50-TCTATGCCTGGAAGAG
GATGGAGGTCG-30 (forward) and 5-TGCGGAAAGTGTCAGCAGTGATTG
TTC-30 (reverse); HIF-2a human 50-AGGACTACAGCCTGTCGTCAGC-30
(forward) and 50-GAGGTGCGAGGACGTTCC-30(reverse); PHD2 human 50-
GCACGACACCGGGAAGTT–30 (forward) and 50-CCAGCTTCCCGTTAC
AGT-30 (reverse); GAPDH human 50-TCCACTGGCGTCTTCACC-30(for-
ward) and 50-GGCAGAGATGATGACCCTTTT-3 (reverse); EPO mouse 50
CATCTGCGACAGTCGAGTTCTG-30(forward) and 50-CACAACCCATCGTGA-
CATTTTC-30(reverse); GAPDH mouse 50-GTCGGTGTGAACGGATTTG–30
(forward) and 50-GAATTTGCCGTGAGTGGAGT-30 (reverse).
Cell culture and animal studies
Renal interstitial fibroblasts TK173 [42] and HepG2 cells (from Ameri-
can Type Culture Collection; Rockville, MD, USA) were maintained in
culture medium, and plates were coated with COLI or COLIV following
previous descriptions [43]. For experiments, cells were grown for the
indicated times in serum-deprived DMEM. For hypoxia conditions, cells
were incubated in one hypoxia workstation (Ruskinn Invivo200) at 1%
O2, 5%CO2 and 94% N2 for 24 hrs. Unilateral ureteral obstruction
(UUO) was performed in C57BL/6 mice as previously described in 44.
Ligation was maintained for 15 days until the mice were killed, and
13 days after obstruction, some animals received bortezomib (750 lg/
Kg i.p., in isotonic saline), an inhibitor of proteasome activity, or iso-
tonic saline. In all procedures, mice were treated in accordance with the
Recommendations of the Helsinki Declaration on the Advice on Care
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and Use of Animals referred to in: law 14\/2 007 (3 July) on Biomedical
Research, Conseil de l0Europe (published in Official Daily N. L358/1-
358/6, 18-12-1986), Government Spanish (Royal Decree 223/1 988, (14
March) and Order of 13-10-1989, and Official Bulletin of the State b.
256, pp. 31349-31362, 28-10-1990). The procedure was approved for
the Bioethics committee of the University of Salamanca.
Renal tissue preparation
Obstructed and non-obstructed kidneys were recovered 15 days after
surgery and perfused with heparinized saline solution. Next, kidneys
were halved longitudinally in order to use one half for protein and RNA
extraction and the other half for histological studies. Renal samples for
protein and mRNA extraction were frozen in liquid nitrogen and stored
at 80°C and for histological studies were fixed in formaldehyde for
24 hrs and then embedded in paraffin.
Histochemistry and double-immunofluorescence
3 lm sections were cut from paraffin-embedded samples and stained
with Masson’s trichrome and Sirius red staining [44]. Sirius red staining
was evaluated by a quantitative scoring system, Image-Pro Plus software
(Media Cybernetics, Bethesda, MD, USA) in five randomly selected fields
per kidney (9200). For double-immunohistochemistry, heat-induced anti-
gen unmasking was performed in Tris 10 mM–EDTA 1 mM, pH 8.00 and
washed with PBS. Sections were incubated simultaneously with anti-a-
SMA and anti-HIF2a antibodies for 1 hr at room temperature. Following
three washes in PBS, sections were incubated with anti-rabbit Cy3 and
antimouse 488 Alexa, diluted 1:1000 for 45 min. at room temperature,
washed in PBS and stained with 2 mM Hoechst. Slides were rinsed in
PBS and mounted in Prolong antifade (Invitrogen, Barcelona, Spain).
Images were photographed with a Zeiss Axiovert 200M microscope (Bar-
celona, Spain) and a Zeiss LSM 510 confocal module (Barcelona, Spain).
Proteasome activity
Cells were plated over COLIV or COLI at indicated times. Then, they were
lysed in lysis buffer (50 mM Tris–HCl, pH 7.4, 5 mM MgCl2, 2 mM DTT and
2 mM ATP). Samples were frozen at 80°C and thawed three times and
then centrifuged for 10 min. at 10,000 9 g. Proteasome activity was mea-
sured in the supernatant fraction using the fluorogenic substrate (80 lM)
Succ-LLVY-AMC. Equal fractions of the supernatants were pre-incubated
with the proteasome inhibitor MG132 (10 lM), for 30 min. at 37°C before
addition of the substrate. The fluorescence was determined by Lumines-
cence spectrometer LS50 (Perkin Elmer, Wellesley, MA, USA) (380 nm exci-
tation wavelength and 460 nm emission wavelength). Activities of enzymes
were measured as arbitrary unit/min/mg protein and then expressed as per-
centage of the activity found in cells plated on COLIV, used as control cells.
Western blot
Treated cells were washed with cold PBS, lysed in buffer (50 mM Trizma,
pH 8.0, 150 mM NaCl, 0.1% Triton X-100, 10 mM EDTA, 0.25% sodium
deoxycholate and protease inhibitors) and were finally sonicated. Protein
samples were run onto 8–12% SDS-PAGE gels and then were transferred
to PVDF membranes, which were blocked with 5% non-fat dry milk or 3%
BSA in TBS-T (50 mM Trizma, pH 7.6, 150 mM NaCl, 0.1% Tween-20).
Membranes were incubated overnight at 4°C with the corresponding pri-
mary antibodies and then incubated with secondary antibodies at room
temperature for 1 hr. Immunoblots were detected by chemiluminescence.
Densitometry analyses were performed with NIH ImageJ software (http://
rsbweb.nih.gov/ij/).
Quantitative reverse transcription PCR
Total RNA was extracted and quantified, and 2 lg of total RNA was
retrotranscribed to cDNA with High Capacity cDNA Reverse Transcrip-
tion Kit. 250 ng of this cDNA was used as a template for PCR amplifi-
cation with the LC FastStart DNA master SYBR Green I Kit following the
manufacturer’s instructions. The normalized gene expression method
(2DDCT) for relative quantification of gene expression was used.
Small-interfering RNA transfection
To deplete expression of FAK protein, a specific small-interfering RNA
(siRNA) was used. Cells were transfected in 1 ml of OPTIMEM with 200 nM
siRNA or Silencer TM negative control (Scrambled RNA) using lipofectamine
2000 for 24 hrs. Then, 1 ml of medium DMEN containing FCS was added for
24 hrs. Afterwards, cells were plated on COLIV or COLI as indicated above.
Transient transfection and Luciferase assays
Cells were transfected using lipofectamine reagent with 0.1 lg of reporter
plasmid p9HIF1-Luc (kindly provided by Dr. Landazuri, University
Autonoma, Madrid) and 0.01 lg of Renilla plasmid luciferase reporter as
internal control. Afterwards, the cells were treated and lysed, and their
luciferase activity was measured with Dual-Luciferase Reporter Assay
System according to the manufacturer’s instructions in a Lumat LB9506
luminometer (Berthold Technologies, Herts, UK). Luciferase activity was
normalized based on Renilla luciferase activity and protein content.
Statistical analysis
Results are expressed as the mean  standard error of the mean (S.E.M.)
of a variable number of independent experiments detailed in Figure Legends.
Some experiments are presented as fold increase or percentage of control
values. In the in vitro experiments, comparisons were performed by the
Student’s t-test (two groups) or one or two-way ANOVA (three or more
groups, one or two variables). In the in vivo experiments, the Mann–Whit-
ney test was used. A P < 0.05 was considered statistically significant.
Results
Culture on COLI induces EPO downregulation in
interstitial fibroblast
To analyse the effects of changes in the ECM composition on EPO
synthesis, TK173 cells, a line of renal interstitial fibroblast, were used.
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TK173 cells were grown on COLI or COLIV for variable times. Fig-
ure 1A shows that EPO mRNA expression was significantly lower at
48 hrs and at 72 hrs culture on COLI with respect to COLIV, suggest-
ing a time-dependent regulation of hormone synthesis in the presence
of COLI in the culture substrate. The observed changes also depended
on the proportion of COLI. In cells plated with different collagen
proportions for 48 hrs, we observed a proportion-dependent
decrease in EPO mRNA: when COLI proportion augmented, EPO
mRNA decreased (Fig. 1B). Changes in EPO mRNA were confirmed
by analysing EPO protein content by Western blot. We observed a sig-
nificant decrease in EPO protein in cells cultured on COLI compared
to COLIV for 48 hrs (Fig. 1C). Similar COLI-dependent changes in
Fig. 1 Collagen I down-regulates erythro-
poietin mRNA and protein levels in intersti-
tial fibroblast cells. (A) Cells were grown on
plates collagen IV (COLIV) or collagen I
(COLI) for 24, 48 and 72 hrs. Erythropoi-
etin mRNA levels were determined by
quantitative RT-PCR. Relative fold change
values were normalized against GAPDH as
endogenous control and expressed as fold
induction over COLIV. (B) Cells were grown
on plates coated with different proportions
of COLIV/COLI for 48 hrs. Erythropoietin
mRNA levels were determined by quantita-
tive RT-PCR. Relative fold change values
were normalized against GAPDH as
endogenous control and expressed as fold
induction over COLIV. (C) TK173 cells and
(D) HepG2 cells were grown on COLIV or
COLI for 48 hrs. EPO protein levels and
GAPDH as endogenous control were evalu-
ated by immunoblotting. A representative
blot is shown. Bar graphs represent per-
centage of densitometric levels versus
COLIV as control. (E) TK173 cells were
submitted under normoxia or hypoxia (1%
O2) conditions for 24-hrs EPO protein
levels and GAPDH as endogenous control
was evaluated by immunoblotting. A
representative blot is shown. Bar graphs
represent percentage of densitometric
levels versus control. Results
are mean  S.E.M.; N = 3-5 independent
experiments (*P < 0.05 versus COLIV;
**P < 0.01).
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EPO protein content were observed in other well-known EPO-produ-
cing cells, HepG2 (Fig. 1D). Hypoxia, the physiological stimulus of
EPO synthesis, increased EPO protein levels in TK173 cells after
24 hrs (Fig. 1E). Taken together, these results indicate that erythro-
poietin is down-regulated in a time- and proportion-dependent man-
ner when cells are grown on COLI versus COLIV.
Culture on COLI induces HIF2a degradation
HIF2a is the main transcription factor involved in the regulation of
EPO synthesis in kidney. To analyse its implication in the above-men-
tioned EPO synthesis dependency on COLI presence, we analysed
mRNA and HIF2a protein levels, as well as HIF activity, in cells cul-
tured on COLI or COLIV. Figure 2A shows no differences in HIF2a
mRNA levels In contrast, we observed a significant decrease in HIF2a
protein levels in cells grown on COLI compared to COLIV cultured
cells (Fig. 2B). To determine HIF activity, we used a hypoxia-respon-
sive element (HRE)-driven reporter construct. A luciferase plasmid
that contained nine copies of the human HIF binding sequence
located between positions 985 and 951 of the 50-human vascular
endothelial growth factor gene promoter [45] was transiently trans-
fected into cells. In this assay, cells cultured on COLI showed a signif-
icantly lower luciferase HIF activity compared to COLIV and
significantly increased when cells were under hypoxia conditions for
24 hrs (Fig. 2C). These results demonstrate that HIF2a protein
decreases in cells cultured on COLI by a mechanism independent of
mRNA expression and probably dependent on HIF2a degradation.
Culture on COLI does not affect the prolyl
hydroxylase-2 activation but increases
proteasome activity
As PHD enzymes regulate HIF degradation, we analysed the expres-
sion of these enzymes in human fibroblasts. We found that PHD2 was
the predominant form detected in these cells. Neither its mRNA
expression (Fig. 3A) nor its protein content (Fig. 3B) was modified by
the two collagens used as culture substrate. To ensure that HIF2a
degradation was not dependent on a PHD increased activity, we stud-
ied HIF hydroxylation with a specific antibody that recognizes HIF
hydroxylated in the presence of the proteasome inhibitor MG132 to
avoid hydroxylated protein degradation. We did not observe any
increment of HIF hydroxylation in cells grown on COLI with respect to
COLIV grown cells (Fig. 3C). Thereafter, to study the relevance of the
main pathway involved in HIF degradation, we measured proteasome
activity in cells cultured in both types of collagens tested. Cells cul-
tured on COLI showed a higher proteasome activity than those cul-
tured on COLIV (Fig. 3D). When proteasome activity was inhibited by
MG132, EPO mRNA expression (Fig. 3E) and HIF-2a protein level
(Fig. 3F) were similar in COLI than in COLIV grown cells. These
results support the premise that COLI effects on EPO synthesis are
mediated by the direct induction of proteasome activity.
Fig. 2 Collagen I down-regulates HIFa protein and activity levels in
interstitial fibroblast cells. Cells were grown on collagen IV (COLIV) or
collagen I (COLI) for 48 hrs. (A) HIF2a mRNA levels were determined
by quantitative RT-PCR. Relative fold change values were normalized
against GAPDH as endogenous control and expressed as fold induction
over COL IV as control. (B) HIF2a protein levels and GAPDH as
endogenous control were evaluated by immunoblotting. A representa-
tive blot is shown. Bar graphs represent percentage of densitometric
levels versus COLIV as control. (C) Luciferase activity was determined
in lysates of cells transfected with a reporter as indicated in methods.
Each bar represents the luciferase activity normalized by the Renilla
luciferase activity and expressed as arbitrary units. Results are
mean  S.E.M.; N = 3 independent experiments (*P < 0.05 versus
COLIV).
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COLI-dependent HIF2a-EPO downregulation and
increased proteasome activity are mediated by
FAK
Collagens are ligands of integrins whose interaction produces a
conformational change that initiates signalling cascade involving
the integrin mediators ILK and FAK. First, we analysed ILK pro-
tein content and activity in cells plated on COLIV or COLI for
48 hrs. Our data show that no changes were observed in ILK
protein content and activity measured as GSK3b protein phos-
phorylation on either of the collagens tested (Fig. 4A and B,
respectively). Otherwise, we analysed FAK activation. Cells incu-
bated on COLI exhibited a sustained increase in FAK tyrosine
phosphorylation compared to cells plated on COLIV (Fig. 4C). To
establish the relevance of COLI-dependent FAK activation in the
previously described changes observed in COL I grown cells,
FAK was deleted in cells with a specific siRNA (siFAK), which
almost completely abrogated FAK expression (Fig. 5A). In
Fig. 3 Collagen type I does not affect prolyl hydroxylases activity, increases proteasome activity and proteasome inhibition restores erythropoietin
levels. Cells were grown on collagen IV (COLIV) or collagen I (COLI) for 48 hrs. (A) PHD2 mRNA levels were determined by quantitative RT-PCR.
Relative fold change values were normalized against GAPDH as endogenous control and expressed as fold induction over COLIV as control. (B)
PHD2 protein levels and GAPDH as endogenous control were evaluated by immunoblotting. A representative blot is shown. (C) Cells were grown on
COLIV or COLI for 24 hrs and then treated with proteasome inhibitor MG132 for another 24 hrs. Hydroxylated-HIF1a protein levels and actin as
endogenous control were evaluated by immunoblotting. A representative blot is shown. (D) Cells were grown on collagen IV (COLIV) or collagen I
(COLI) for 48 hrs. Proteasome activity was measured as fluorogenic chymotrypsin substrate in a fluorimeter. Data are shown as the percentage of
activity measured on COLIV. Cells were grown on COL IV or COLI for 24 hrs and then treated with proteasome inhibitor MG132 for another 24 hrs.
(E) Erythropoietin mRNA levels were determined by quantitative RT-PCR. Relative fold change values were normalized against GAPDH as endoge-
nous control and expressed as fold induction over COLIV. Data are shown as the percentage of activity measured on COLIV. (F) HIF2a protein levels
and GAPDH as endogenous control were evaluated by immunoblotting. A representative blot is shown. Bar graphs represent percentage of densito-
metric levels versus COLIV as control. Results are mean  S.E.M.; N = 3 independent experiments (*P < 0.05 versus the other groups).
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absence of FAK, proteasome activity (Fig. 5B), HIF2a protein con-
tent (Fig. 5C) and EPO mRNA expression were similar in COLI
than in COLIV grown cells (Fig. 5D). PP2, a selective inhibitor of
FAK activation, exerted the same effects as siFAK on the COLI-
induced EPO mRNA downregulation (Fig. 5E). These results show
that FAK is a relevant integrin-linked protein involved in the EPO
modulation induced by COLI.
EPO synthesis decreases after unilateral ureteral
obstruction (UUO) and is recovered after
proteasome inhibition
The UUO model of tubulointerstitial fibrosis is characterized by the
abnormal accumulation of ECM proteins in the obstructed kidney
compared to the contralateral non-obstructed organ. 15 days after
surgery, we observed an increased COLI content (Fig. 6A) and fibro-
sis (Fig. 6B) in obstructed kidneys (O) compared to non-obstructed
(NO) control organs, in agreement with previous results [44]. In these
experimental conditions, EPO mRNA levels in renal cortex almost
completely disappeared in O kidneys (Fig. 6C). With respect to FAK
activation, an increased tyrosine phosphorylation of the protein was
detected by Western blot in renal cortex from kidneys, but the differ-
ences with the NO kidney were not statistically significant (Fig. 6D).
The basal HIF2a content in NO kidneys was almost undetectable by
immunohistochemistry. Surprisingly, O kidneys showed marked over-
expression of the protein in renal epithelial tubular cells but not in
interstitial fibroblast, as demonstrated by the lack of co-localization of
HIF2a with the fibroblast marker a-SMA (Fig. 6E). Furthermore,
obstructed kidneys from UUO mice treated with the proteasome inhi-
bitor, bortezomib, showed similar levels of extracellular matrix than O
kidneys from mice non-treated with bortezomib (Fig. 7A and B). In
this context of proteasome inhibition and also similar levels of extra-
cellular matrix levels, EPO mRNA levels were higher than the O kid-
neys from non-treated mice (Fig. 7C).
Discussion
One of the main clinical problems in patients with CKD is anaemia.
Different factors are responsible for the decreased erythrocyte num-
ber in renal patients, being the most relevant in most cases a reduced
EPO synthesis. In fact, treatment with human recombinant EPO
(rhEPO) significantly improves the anaemia of these patients. Other
factors implicated in renal anaemia are blood loss, shortening of red
blood cell lifespan, malnutrition, reduced iron availability, and inhibi-
tion of the growth of erythrocytic progenitors by inflammatory cytoki-
nes and uraemic toxins. The mechanism by which EPO synthesis
deficiency develops in CKD subjects has been attributed to a decrease
in the number of kidney EPO-producing cells. EPO seems to be syn-
thesized by a particular subtype of interstitial fibroblast and the loss
of these cells, in the progressive interstitial fibrosis that characterizes
CKD, has been supposed to be the cause of EPO deficiency [46].
However, alternative mechanisms, like phenotypic changes of
Fig. 4 Collagen I activates focal adhesion kinase (FAK) but not ILK. Cells
were grown on collagen IV (COLIV) or collagen I (COLI) for 48 hrs. (A)
ILK protein and GAPDH as endogenous control, (B) Phospho-GSK protein
and Total-GSK as endogenous control and (C) Phospho-FAK protein and
Total-FAK as endogenous control were evaluated by immunoblotting. A
representative blot of each one is shown. Bar graphs represent percentage
of densitometric levels versus COL IV. Results are mean  S.E.M.; N = 3
independent experiments (*P < 0.05 versus COLIV).
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Fig. 5 Deleted FAK restored proteasome activity at basal levels, inhibits HIF-2a degradation and restores erythropoietin levels. Cells were depleted of
FAK with a specific small-interfering RNA (siFAK), and a scrambled RNA (Scramble) was used as control. (A) Expression of Total-FAK protein was
analysed by Western blot. Equal protein loading was confirmed by probing with actin as endogenous control. A representative Western blot is
shown. Cells transfected with siRNA against FAK protein or scramble were grown on collagen IV (COLIV) or collagen I (COLI) for 48 hrs. Then, it
was determined: (B) Proteasome activity measured as fluorogenic chymotrypsin substrate in a fluorimeter. Data are shown as the percentage of
activity measured on COLIV. (C) HIF2a protein levels and actin as endogenous control were evaluated by immunoblotting. A representative blot is
shown. (D) Erythropoietin mRNA levels were determined by quantitative RT-PCR. Relative fold change values were normalized against GAPDH as
endogenous control and expressed as fold induction over COLIV. (E) Cells were grown on collagen IV (COLIV) or collagen I (COLI) for 24 hrs and
then incubated with the FAK inhibitor 4-amino-5-(4-chloro-phenyl)-7-(t-butyl) pyrazolo3,4-dpyrimidine (PP2) 10 lM for other 24 hrs. Erythropoietin
mRNA levels were determined by quantitative RT-PCR. Relative fold change values were normalized against GAPDH as endogenous control and
expressed as fold induction over COLIV. Results are mean  S.E.M.; N = 3 independent experiments (*P < 0.05 versus the other groups).
Fig. 6 EPO decreased in kidneys with tubulointerstitial fibrosis induced by unilateral ureteral obstruction (UUO). (A) Collagen I protein levels and
GAPDH as endogenous control were evaluated by immunoblotting in non-obstructed (NO) and obstructed (O) kidneys. A representative blot is
shown. Bar graphs represent percentage of densitometric levels. (B) Representative images of the renal cortex stained with Sirius red of non-
obstructed (NO) and obstructed (O) kidneys. Bar = 100 lm. (C) Erythropoietin mRNA levels from renal cortex were determined by quantitative RT-
PCR. Relative fold change values were normalized against GAPDH as endogenous control and expressed as fold changes over non-obstructed (NO)
kidney. (D) Phosphorylated-FAK protein levels and GAPDH as endogenous control were evaluated by immunoblotting. A representative blot is
shown. Bar graphs represent percentage of densitometric levels. (E) Representative images of the renal cortex stained with specific antibodies corre-
sponding to non-obstructed (NO) and obstructed (O) kidneys: aSMA (Green); HIF2a (red), nucleus (blue). Bar = 20 lm. Data are means  S.E. of
five to seven animals/group.*P < 0.05 versus non-obstructed kidney.
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Epo-producing renal fibroblasts, that trans-differentiate to scar-pro-
ducing myofibroblasts [47], could be proposed to explain the reduced
EPO synthesis. Fibroblast phenotypic changes could be the conse-
quence of the same noxious stimuli that damage kidney structures,
but they could also be explained by the abnormal ECM protein accu-
mulation in the renal interstitium.
Renal fibroblasts are a heterogeneous cellular population which
have several functions as extracellular matrix production [48], vas-
cular integrity support [49] and EPO synthesis [50]. It has not still
been possible to separate and cultivate these different types of
cells for a better study and thus, many studies about EPO synthe-
sis regulation have been conducted with EPO-producing hepatoma
cells. However, this hepatoma cell model does not appear to be
the most adequate to study CKD-dependent EPO synthesis defi-
ciency, particularly because the mechanism of EPO regulation in
liver is different than in kidney [51]. Taken into account this fact,
the present work was conducted in interstitial fibroblast TK173 as
a model closer to the kidney. Under the experimental conditions
selected, EPO synthesis by TK173 cells appears comparable to that
of hepatome-derived cells, and its expression depends on the O2
partial pressure, as observed in the experiments under hypoxic
conditions.
We observed that the interstitial renal fibroblast cultured on plates
coated with COLI, a fibrillar collagen that is not usually present in the
renal interstitium but that appears under pathophysiological condi-
tions, exhibited a time-dependent decrease in EPO mRNA levels and
protein content compared to cells grown on COL IV, considered the
physiological collagen component of renal ECM, as it is a major com-
ponent of epithelial basal membranes [9]. As interstitial fibrosis could
be better mimicked by a variable mix of different ECM proteins than
by a complete substitution of COLIV by COLI, we assessed EPO syn-
thesis when cells were plated on a collagen mixture with variable
Fig. 7 EPO mRNA is recovered in
obstructed kidneys of mice with UUO trea-
ted with proteasome inhibitor bortezomib.
(A) Representative images of the renal
cortex stained with (A) Masson’s tri-
chrome and (B) Sirius red and quantifica-
tion by Image-Pro Plus expressed as
square microns corresponding to non-
obstructed (NO), obstructed (O), non-
obstructed treated with bortezomib (NO-B)
or obstructed treated with bortezomib (O-
B) kidneys. Bar = 100 lm. (C) Erythropoi-
etin mRNA levels from renal cortex from
NO, O, NO-B and O-B kidneys were deter-
mined by quantitative RT-PCR. Relative
fold change values were normalized
against GAPDH as endogenous control
and expressed as fold changes over non-
obstructed (NO) kidney. Data are
means  S.E. of five to seven animals/
group. *P < 0.05 versus non-obstructed
kidney.
10 ª 2017 The Authors.
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COLI and COLIV concentrations, and we observed differences in EPO
synthesis depending on the ratio COLI/COLIV concentrations in the
collagen mixture. Thus, our results support the biological relevance of
the COLI-dependent EPO downregulation as these results show a
relationship between ECM composition and EPO synthesis. To our
knowledge, this is the first report of the relationship between compo-
sition of collagen types and EPO synthesis in renal cells. However, it
has been suggested that renal fibrosis may determine phenotypic
changes in interstitial fibroblasts in response to microenvironmental
changes that would range from an EPO synthesizing to a matrix pro-
ducing phenotype, thus conditioning a decreased EPO synthesis with
the subsequent anaemia [41].
HIF is the main responsible transcription factor for the EPO induc-
tion [24]. Although some papers have reported that HIF can be regu-
lated by integrins in hypoxic conditions [52], there is no clear
evidence of this regulation. As a number of evidence show that iso-
form HIF2a can be the main regulator of EPO in vivo in adult kidney
(26, 32), we decided to study the regulation of this isoform. We
observed that HIF2a protein and activity were down-regulated in cells
cultivated on COLI with respect to COLIV, without changes in mRNA
expression, suggesting a non-transcriptional regulation but an
increased HIF2a degradation. To determine the mechanism through
which HIF2a is excessively degraded in TK173 cells plated on COLI,
we studied some proteins involved in HIF pathway such as PHD and
VHL. We analysed PHD isoforms, but only PHD2 is expressed in
these cells. We found that PHD2 mRNA, protein expression and
its activity measured as HIF hydroxylation were similar in cells on
COLI with respect to COLIV. Moreover, VHL mRNA and protein
expression were not modified by the type of collagen (data not
shown). As HIF2a is degraded by proteasome, we measured pro-
teasome activity and observed that it was significantly higher in
cells harvested on COLI than in those on COLIV. When we inhib-
ited proteasome activity with the inhibitor MG132, EPO mRNA
levels and HIF2a protein expression in cells on COLI were similar
to those observed in cells on COLIV. Although it has been
described that proteasome inhibitors do not increase HIF activity
but only the amount of protein, in our hands it increases not only
cellular HIF2a protein content but also restore interstitial fibroblast
EPO synthesis to a level similar to that observed for COL IV. Addi-
tional studies are needed to better clarify these effects, but our
results propose an alternative way to modulate HIF2a protein
levels, and subsequently EPO synthesis, in CKD patients.
FAK, and not ILK, seems to be the protein responsible for COLI-
induced changes in EPO synthesis because neither ILK protein
expression nor activity, measured as GSK3ß phosphorylation, chan-
ged in cells cultured on COLI compared with those on COLIV. In con-
trast, FAK phosphorylation at Tyr397 was significantly higher in cells
on COLI than in those on COLIV, without changes in total-FAK con-
tent, supporting a higher activation of the protein after exposition to
COLI. Moreover, FAK blockade by mRNA depletion or pharmacologi-
cal treatment inhibited the COLI-dependent increased proteasome
activity and restored the decreased HIF2a protein content and EPO
mRNA expression to values similar to those observed in fibroblasts
cultured on COLIV. This finding constitutes an additional support to
the biological relevance of the interaction between fibroblasts and
ECM in the process of EPO synthesis, as FAK is considered a critical
protein in the regulation of the cross-talk ECM cells.
To gain more insight into the pathophysiological meaning of our
results in cells, as well as to explore new possibilities of increasing
EPO synthesis in chronically damaged kidneys, we used a model of
tubulointerstitial fibrosis induced by UUO. This model is characterized
by the presence of myofibroblast from different origins and increased
accumulation of ECM proteins at interstitial level [53, 54]. In the
obstructed kidney of UUO mice, it was observed tubulointerstitial
fibrosis, a significant increase in COLI and a significant decrease in
EPO mRNA expression, with respect to the contralateral non-
obstructed kidneys. These mice did not have anaemia because the
ureteral obstruction was performed only in one kidney.
Although FAK phosphorylation was higher in the obstructed than
in non-obstructed kidneys, the differences were not statistically sig-
nificant. Protein phosphorylation is a rather quick mechanism of regu-
lation of their activity, and it may occur that after 15 days of
obstruction the changes in FAK phosphorylation were no longer
detected. On the other hand, we did not observe the reduction of
HIF2a content that we observed in cells grown on COLI, in the fibrotic
kidneys. Surprisingly, we observed a marked increment of the level of
this protein in total renal cortex (data not shown), apparently in con-
tradiction with the almost complete disappearance of EPO expression.
It should be noted that total cortex analysed in the kidneys is com-
posed with many cell types, probably with different behaviour with
respect to the phenomenon studied, and the most predominant cell
type are tubular epithelial cells. To analyse this discrepancy, we per-
formed an immunohistochemistry to study HIF2a expression. The
protein increased in tubular epithelial cells, but not in EPO-producing
cells, interstitial fibroblast, in which EPO was completely absent.
Interestingly, obstructed kidneys of mice treated with the proteasome
inhibitor bortezomib showed a level of EPO synthesis similar to non-
obstructed kidney levels. These data support our in vitro findings,
suggesting that proteasome activity is augmented in fibrosis, and it
could be involved in EPO downregulation observed.
In summary, our data point to a new mechanism of anaemia
development in patients with CKD. The in vitro findings clearly sup-
port that COLI accumulation that takes place in renal fibrosis induces
FAK activation in EPO-producing interstitial fibroblasts, which in its
turn increases proteasome activity. Proteasome degrades HIF2a with
the subsequent EPO downregulation. In vivo findings also support
this contention.
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